FancD2 colocalizes in vivo with another protein in SiHa cells after cell exposure to IR. Proliferating SiHa cells were exposed to 10 Gy of IR and double -color immunofluorescence staining was performed after 8 h. Images were captured in a Kodak digital image system on a Leica fluorescence microscope.
|Tested species reactivity||Human, Mouse, Non-human primate|
|Published species reactivity||Human|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Human FANCD2 fusion protein (N-terminal fragment).|
|Contains||0.05% sodium azide|
|Storage Conditions||-20° C, Avoid Freeze/Thaw Cycles|
|Tested Applications||Dilution *|
|Flow Cytometry (Flow)||Assay-Dependent|
|Immunohistochemistry (IHC)||2.5-5.0 µg/ml|
|Immunohistochemistry (Paraffin) (IHC (P))||2.5-5 µg/ml|
|Western Blot (WB)||1:10,000-1:20,000|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Immunohistochemistry (IHC)||See 1 publications below|
In Western blot, this antibody should recognize a band at ~166 kDa (post-translationally modified form).
Additional bands may be seen at lower molecular weights.
In immunofluorescence, this has been tested in human MMC and IR-treated MEF cells.Suggested positive control: Hela whole cell extract.
Fanconi anemia (FANC) is a human autosomal-recessive cancer susceptibility disorder characterized by congenital defects, progressive bone marrow failure, and cellular hypersensitivity to mitomycin C (MMC). The FANC subunit D2 protein is vital for cellular resistance to DNA cross-linking and the arrest of DNA synthesis after ionizing radiation. DNA damage activates the monoubiquitination of FANCD2, targeting nuclear foci containing the BRCA1 protein.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Gene expression profiling reveals activation of the FA/BRCA pathway in advanced squamous cervical cancer with intrinsic resistance and therapy failure.
PA1-16548 was used in immunohistochemistry to study the gene expression profiles of patients with locally advanced squamous cervical cancer to identify pathways responsible for therapeutic failure
|Balacescu O,Balacescu L,Tudoran O,Todor N,Rus M,Buiga R,Susman S,Fetica B,Pop L,Maja L,Visan S,Ordeanu C,Berindan-Neagoe I,Nagy V||BMC cancer (14:null)||2014|